Takeda has presented data from a post-hoc analysis showing signs of early symptomatic improvement in patients with ulcerative colitis or Crohn’s disease taking Entyvio. More: New analysis backs use of Takeda’s Entyvio Source: News
read moreEuropean regulators have awarded Ignyta’s cancer drug entrectinib Priority Medicines (PRIME) designation, potentially placing the treatment on a faster path to approval. More: PRIME status for Ignyta’s entrectinib Source: News
read moreJohnson & Johnson may have incidentally scored a major victory in the Supreme Court case brought by another drugmaker, Bristol-Myers Squibb. Because of a Bristol ruling this summer, J&J has escaped a $72 million verdict in its ongoing talcum powder
read moreSurprise, surprise: Impax Labs, looking to bulk up amid generics pricing pressure and newly helmed by M&A specialist Paul Bisaro, has struck a deal. More: Bisaro steers Impax to .4B Amneal merger, creating fifth-largest U.S. generics company Source: fierce
read moreUnder a growing biosimilar assault, Johnson & Johnson’s big-selling immunology biologic Remicade held its ground again in the third quarter. Now, executives are planning their 2018 defense strategy for a critical medication that leads sales for the drug giant. More:
read moreIn the wake of Hurricane Maria, Johnson & Johnson executives say its Puerto Rico manufacturing facilities weathered the storm well and are getting back up to full speed, though some drug supplies could run short. More: Johnson & Johnson says
read more© 1994 - 2026 B.M. Pharmaceuticals